RxDoctor Payments DataLook up a doctor →

Andrzej Maciejewski, MD

Nephrology · Anchorage, AKNPI 1194780114

Payments from drug & device makers

$59,909in general payments, 2019–2025

Across 799 payments — averaging $74.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$39K
  • Johnson & Johnson$4K
  • AstraZeneca$3K
  • Novartis$2K
  • Lilly USA, LLC$1K
  • Merck$893
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$3751%
  • Speaking & faculty fees$33,19555%
  • Travel & lodging$4,4958%
  • Food & beverage$21,77136%
  • Education$730%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)118$38,558
Johnson & Johnson12$3,717
AstraZeneca(2 entities)94$3,339
Novartis60$1,583
Lilly USA, LLC68$1,363
Merck48$893
AbbVie(2 entities)45$869
Novo Nordisk52$824
Sanofi-aventis U.S. LLC28$753
Medtronic(2 entities)24$723
Boehringer Ingelheim16$526
Averitas Pharma Inc.39$473
Takeda Pharmaceuticals U.S.A., Inc.19$406
GSK3$357
Antares Pharma, Inc.1$323
Bayer13$320
Otsuka America Pharmaceutical, Inc.9$319
Abbott11$278
Kyowa Kirin, Inc.7$263
Radius Health, Inc.5$260
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$250
ANI Pharmaceuticals, Inc.8$238
E.r. Squibb & Sons, L.L.C.7$229
Otsuka Pharmaceutical Development & Commercialization, Inc.2$200
Calliditas Therapeutics US Inc.9$197
Amarin Pharma, Inc.8$191
Portola Pharmaceuticals, LLC4$189
Ascendis Pharma Endocrinology Inc2$180
Eisai Inc.10$141
Pfizer7$133
Aurinia Pharma U.S., Inc.6$127
Neurocrine Biosciences, Inc.1$125
Astellas Pharma US Inc2$122
Biohaven Pharmaceutical Holding Company Ltd.1$122
Corcept Therapeutics5$110
UCB, Inc.2$105
Medicure Pharma Inc.1$101
Vifor Pharma, Inc.5$98
Xeris Pharmaceuticals, Inc.5$93
Mallinckrodt Hospital Products Inc.5$91
Ultragenyx Pharmaceutical Inc.1$78
Mallinckrodt Enterprises LLC4$68
Madrigal Pharmaceuticals2$61
Aimmune Therapeutics, Inc.2$48
Insulet Corporation2$45
IBSA Pharma Inc.2$44
Endo Pharmaceuticals Inc.2$40
Travere Therapeutics, Inc.2$39
Arbor Pharmaceuticals, Inc.2$36
RGH Enterprises LLC1$36
Lundbeck LLC2$31
Regeneron Healthcare Solutions, Inc.1$30
Cycle Pharmaceuticals Inc1$29
Dexcom, Inc.2$27
Recordati_rare_diseases_inc.1$24
Amryt Pharma Holdings Ltd1$21
Azurity Pharmaceuticals, Inc.1$20
Nevro Corp.1$15
Nestle Healthcare Nutrition Inc.1$15
Esperion Therapeutics, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few nephrology providers in Alaskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$259,723
Medicare patients
509
Services billed
10,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol186$246,186
MounjaroTirzepatide126$159,814
JardianceEmpagliflozin99$138,357
Tresiba Flextouch U-200Insulin Degludec128$114,870
OzempicSemaglutide71$99,480
Cosentyx Sensoready (2 Pens)Secukinumab11$79,394
EliquisApixaban46$56,931
JanuviaSitagliptin Phosphate44$44,851
LinzessLinaclotide50$40,758
TrintellixVortioxetine Hydrobromide28$35,289
Fiasp FlextouchInsulin Aspart (Niacinamide)29$30,236
TrulicityDulaglutide16$29,694
KerendiaFinerenone17$26,961
DapagliflozinDapagliflozin Propanediol32$26,533
JanumetSitagliptin Phos/Metformin Hcl25$22,710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$3,339$261,118201 claims
Lilly USA, LLCMounjaro, Trulicity$1,363$189,507142 claims
Boehringer IngelheimJardiance$526$138,35799 claims
Novo NordiskOzempic$824$99,48071 claims
MerckJanuvia, Janumet, Verquvo$893$86,80081 claims
PfizerEliquis, Premarin$133$65,04568 claims
AbbVieLinzess$869$40,75850 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$406$35,28928 claims
BayerKerendia$320$26,96117 claims
Arbor Pharmaceuticals, Inc.Edarbi$36$12,55520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few nephrology providers in Alaskaon file to place this against a meaningful peer group, so we don't.

Other nephrology in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →